Method of Detection of Summed Cardiac Troponins for Cardiovascular Risk Stratification
The present disclosure provides methods for assessing a subject's cardiovascular health. In one embodiment, the method comprises determining a level of cardiac Troponin I and a level of cardiac Troponin T in a sample, and comparing a combined score determined as a function of the cardiac Troponin levels to reference cardiac Troponin levels associated with a reference population. In some embodiments, the present disclosure provides methods of treating a subject, the method comprising determining a level of cardiac Troponin I and a level of cardiac Troponin T in a sample, comparing a combined score determined as a function of the cardiac Troponin levels to reference cardiac Troponin levels associated with a reference population, and initiating a therapeutic regimen in the subject if the combined score is greater than the reference cardiac Troponin levels.
1 . A method of treating or preventing a cardiovascular disease or disorder in a subject, the method comprising:
determining a cardiac Troponin I level and a cardiac Troponin T level in a biological sample of the subject;
calculating an combined score as a function of at least the determined cardiac Troponin I level and the determined cardiac Troponin T level;
comparing the combined score to reference values from a reference population; and
initiating a treatment regimen in the subject if the combined score correlates with a range in a higher unit of an ordered distribution of the reference values.
2 . The method of claim 1 , wherein the cardiovascular disease or disorder is an ischemic event.
3 . The method of claim 1 , wherein the method comprises preventing a cardiovascular morbidity.
4 . The method of claim 1 , wherein the cardiovascular disease or disorder is myocardial damage.
5 . The method of claim 1 , wherein the step of determining the cardiac Troponin I and cardiac Troponin T levels comprises contacting the biological sample with an antibody that binds to both cardiac Troponin I and cardiac Troponin T.
6 . The method of claim 1 , wherein the step of calculating the combined score consists essentially of adding the cardiac Troponin I level and the cardiac Troponin T level.
7 . The method of claim 1 further comprising:
determining a second cardiac Troponin I level and a second cardiac Troponin T level in a second biological sample of the subject;
calculating a second combined score as a function of at least the second cardiac Troponin I level and a second cardiac Troponin T level;
comparing the second combined score to the combined core; and
modifying the treatment regimen in the subject if the second combined score is higher or lower than the combined score.
8 . The method of claim 1 , wherein the step of determining the cardiac Troponin I and cardiac Troponin T levels comprises contacting the biological sample with a monoclonal antibody that binds to both cardiac Troponin I and cardiac Troponin T to a microtiter well or to magnetic or latex beads.
9 . The method of claim 1 further comprising determining a level of at least one additional biomarker in the biological sample, wherein the treatment regimen is initiated if the level of the at least one additional biomarker is outside a normal range for that biomarker.
10 . The method of claim 9 wherein the additional biomarker is selected from the group consisting of: cardiac muscle injury, ischemia, ischemia-reperfusion injury, fibrosis, apoptosis, cardiomyopathy, inflammation, complement cascade, glycemic control, insulin resistance, beta cell dysfunction, exercise physiology, diet, cerebrovascular events, hypertension, kidney function, and cachexia.
11 . The method of any of claims 1 - 4 , further comprising additional markers as part of a composite index score.
12 . The method of claim 1 , wherein the step of determining the cardiac Troponin I level and the cardiac Troponin T level comprises contacting a solid surface with the biological sample, wherein the solid surface comprises at least one capture antibody capable of binding to cardiac Troponin T and at least one capture antibody capable of binding to cardiac Troponin I.
13 . The method of claim 12 , wherein the at least one capture antibody capable of binding to cardiac Troponin T is capable of binding to whole free cardiac Troponin T, a proteolytic fragment of cardiac Troponin T, a post-translational modification of cardiac Troponin T, and/or a complex of cardiac Troponin T.
14 . The method of claim 12 , wherein the at least one capture antibody capable of binding to cardiac Troponin I is capable of binding to whole free cardiac Troponin I, an epitope of cardiac Troponin I that is exposed when it is bound in complex to cardiac Troponin C, an epitope of cardiac Troponin C that is exposed when it is bound in complex to cardiac Troponin I, an epitope unique to a bound cardiac Troponin I:cardiac Troponin C complex, a proteolytic fragment of cardiac Troponin I, and/or a post-translational modification of cardiac Troponin I.
15 . The method of claim 14 , wherein the solid surface further comprises:
at least one secondary antibody, wherein the at least one secondary antibody is capable of binding to a distinct epitope of whole free cardiac Troponin T, a proteolytic fragment of cardiac Troponin T, a post-translational modification of cardiac Troponin T, and/or a complex of cardiac Troponin T compared to an epitope that binds to the at least one capture antibody capable of binding to cardiac Troponin T; and
at least one additional secondary antibody, wherein the at least one additional secondary antibody is capable of binding to a distinct epitope of whole free cardiac Troponin I, an epitope of cardiac Troponin I that is exposed when it is bound in complex to cardiac Troponin C, an epitope of cardiac Troponin C that is exposed when it is bound in complex to cardiac Troponin I, an epitope unique to a bound cardiac Troponin I:cardiac Troponin C complex, a proteolytic fragment of cardiac Troponin I, and/or a post-translational modification of cardiac Troponin I compared to an epitope that binds to the at least one capture antibody capable of binding to cardiac Troponin C.
16 . The method of claim 12 wherein the at least one capture antibody capable of binding to cardiac Troponin T and at least one capture antibody capable of binding to cardiac Troponin I comprise a polyclonal mixture.
17 . The method of claim 5 further comprising contacting the biological sample with:
secondary detection antibodies of identically labelled polyclonal mixtures, wherein the secondary detection antibodies are specific for forms of cardiac Troponin T; and
contacting the biological sample with at least one polyclonal mixture specific to at least cardiac Troponin I, cardiac Troponin C, or both.
18 . The method of claim 12 , wherein the solid surface further comprises:
secondary detection antibodies of identically labelled polyclonal mixtures, wherein the secondary detection antibodies are specific for forms of cardiac Troponin T; and
contacting the biological sample with at least one polyclonal mixture specific to at least cardiac Troponin I, cardiac Troponin C, or both.
19 . The method of claim 1 , wherein the subject is asymptomatic for acute cardiovascular disease.
20 . The method of claim 1 , wherein the subject is negative for biomarkers comprising cardiovascular stress and damage.